Brussels is at the centre of EU decision-making and as such attracts thousands of lobbyists, promoting the interests of big business. Easily outnumbering and outspending public interest groups, corporate lobbyists are also given privileged access by the European institutions. The emerging lobbycracy results in flawed policies that put commercial interests above those of people and the environment and undermines the very basis of democracy.
In the near future, we might see a mandatory register in Denmark. But there are obstacles and pitfalls
Brussels, 25 June - The EU Transparency Register, jointly launched by the European Commission and the Parliament a year ago today (Monday), fails to give a full and accurate picture of lobbying activities in Brussels, according to a new report by the Alliance for Lobbying Transparency and Ethics Regulation (Alter-EU) .
28 March 2012 - New research reveals that the pharmaceutical industry lobby is spending more than €40 million annually to influence decision making in the European Union (EU) – of which nearly half is spent by drug manufacturers on in-house lobbyists.
According to these findings, civil society organisations active on EU medicines issues, on the other hand, spend a combined €3.4 million per year. With the immense disparity between the affluence of public interest groups and the industrial lobby, it becomes even more difficult to level the policy playing field.
Corporate Europe Observatory
Corporate Europe Observatory (CEO) is a research and campaign group working to expose and challenge the privileged access and influence enjoyed by corporations and their lobby groups in EU policy making.